S&P 500   4,122.47 (-0.42%)
DOW   32,774.41 (-0.18%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
S&P 500   4,122.47 (-0.42%)
DOW   32,774.41 (-0.18%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
S&P 500   4,122.47 (-0.42%)
DOW   32,774.41 (-0.18%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
S&P 500   4,122.47 (-0.42%)
DOW   32,774.41 (-0.18%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
NYSE:BIO

Bio-Rad Laboratories - BIO Stock Forecast, Price & News

$518.86
-16.22 (-3.03%)
(As of 08/9/2022 04:34 PM ET)
Add
Compare
Today's Range
$516.28
$533.00
50-Day Range
$463.67
$563.26
52-Week Range
$462.61
$832.70
Volume
104,974 shs
Average Volume
210,769 shs
Market Capitalization
$15.41 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$700.00

Bio-Rad Laboratories MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
34.9% Upside
$700.00 Price Target
Short Interest
Healthy
1.59% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.54
Upright™ Environmental Score
News Sentiment
0.26mentions of Bio-Rad Laboratories in the last 14 days
Based on 14 Articles This Week
Insider Trading
Selling Shares
$278,166 Sold Last Quarter
Proj. Earnings Growth
9.59%
From $14.28 to $15.65 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.93 out of 5 stars

Medical Sector

31st out of 1,098 stocks

Analytical Instruments Industry

4th out of 31 stocks

BIO stock logo

About Bio-Rad Laboratories (NYSE:BIO) Stock

Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. In addition, the company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

Bio-Rad Laboratories Price Performance

Shares of Bio-Rad Laboratories stock traded down $4.57 during trading on Monday, hitting $535.08. 99,576 shares of the stock traded hands, compared to its average volume of 211,474. The company has a quick ratio of 4.22, a current ratio of 5.30 and a debt-to-equity ratio of 0.13. The stock has a market cap of $16.02 billion, a price-to-earnings ratio of -8.07 and a beta of 0.96. The firm's fifty day moving average is $513.07 and its 200-day moving average is $544.65. Bio-Rad Laboratories has a 52 week low of $462.61 and a 52 week high of $832.70.

Bio-Rad Laboratories (NYSE:BIO - Get Rating) last announced its quarterly earnings data on Thursday, July 28th. The medical research company reported $3.38 EPS for the quarter, beating the consensus estimate of $2.46 by $0.92. The firm had revenue of $691.10 million for the quarter, compared to analyst estimates of $664.60 million. Bio-Rad Laboratories had a positive return on equity of 3.82% and a negative net margin of 67.66%. The company's revenue was down 3.5% on a year-over-year basis. During the same period in the prior year, the company earned $3.54 EPS. Research analysts expect that Bio-Rad Laboratories will post 14.28 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have weighed in on the company. Jefferies Financial Group restated a "buy" rating and issued a $700.00 target price on shares of Bio-Rad Laboratories in a research note on Friday, April 29th. Citigroup reduced their price objective on Bio-Rad Laboratories from $750.00 to $700.00 and set a "buy" rating on the stock in a research report on Friday, July 8th. Finally, TheStreet lowered Bio-Rad Laboratories from a "b-" rating to a "c+" rating in a research report on Thursday, April 28th.

Insider Activity at Bio-Rad Laboratories

In related news, CAO Ajit Ramalingam sold 518 shares of the stock in a transaction dated Friday, August 5th. The stock was sold at an average price of $537.00, for a total transaction of $278,166.00. Following the completion of the sale, the chief accounting officer now directly owns 98 shares in the company, valued at approximately $52,626. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 27.40% of the stock is currently owned by company insiders.

Receive BIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bio-Rad Laboratories and its competitors with MarketBeat's FREE daily newsletter.

BIO Stock News Headlines

10 Stocks Billionaire Ken Fisher May Never Sell
Bio-Rad Reports First-Quarter 2022 Financial Results
See More Headlines
Receive BIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bio-Rad Laboratories and its competitors with MarketBeat's FREE daily newsletter.

BIO Company Calendar

Last Earnings
7/28/2022
Today
8/09/2022
Next Earnings (Estimated)
10/27/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Analytical instruments
Sub-Industry
Life Sciences Tools & Services
Sector
Medical
CUSIP
09057220
Employees
7,900
Year Founded
1952

Price Target and Rating

Average Stock Price Forecast
$700.00
High Stock Price Forecast
$700.00
Low Stock Price Forecast
$700.00
Forecasted Upside/Downside
+34.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$4.25 billion
Pretax Margin
-90.90%

Debt

Sales & Book Value

Annual Sales
$2.92 billion
Cash Flow
$15.20 per share
Book Value
$456.60 per share

Miscellaneous

Free Float
21,561,000
Market Cap
$15.41 billion
Optionable
Optionable
Beta
0.96

Social Links















BIO Stock - Frequently Asked Questions

Should I buy or sell Bio-Rad Laboratories stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bio-Rad Laboratories in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BIO shares.
View BIO analyst ratings
or view top-rated stocks.

What is Bio-Rad Laboratories' stock price forecast for 2022?

2 Wall Street analysts have issued 1-year price objectives for Bio-Rad Laboratories' shares. Their BIO share price forecasts range from $700.00 to $700.00. On average, they expect the company's share price to reach $700.00 in the next year. This suggests a possible upside of 34.6% from the stock's current price.
View analysts price targets for BIO
or view top-rated stocks among Wall Street analysts.

How has Bio-Rad Laboratories' stock price performed in 2022?

Bio-Rad Laboratories' stock was trading at $755.57 at the start of the year. Since then, BIO stock has decreased by 31.2% and is now trading at $520.08.
View the best growth stocks for 2022 here
.

When is Bio-Rad Laboratories' next earnings date?

Bio-Rad Laboratories is scheduled to release its next quarterly earnings announcement on Thursday, October 27th 2022.
View our BIO earnings forecast
.

How were Bio-Rad Laboratories' earnings last quarter?

Bio-Rad Laboratories, Inc. (NYSE:BIO) released its quarterly earnings data on Thursday, July, 28th. The medical research company reported $3.38 EPS for the quarter, beating analysts' consensus estimates of $2.46 by $0.92. The medical research company had revenue of $691.10 million for the quarter, compared to analyst estimates of $664.60 million. Bio-Rad Laboratories had a positive trailing twelve-month return on equity of 3.82% and a negative net margin of 67.66%. Bio-Rad Laboratories's quarterly revenue was down 3.5% on a year-over-year basis. During the same quarter last year, the company posted $3.54 earnings per share.
Read the conference call transcript
.

What guidance has Bio-Rad Laboratories issued on next quarter's earnings?

Bio-Rad Laboratories updated its FY 2022 earnings guidance on Thursday, August, 4th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $2.95 billion-$2.95 billion, compared to the consensus revenue estimate of $2.85 billion.

What is Norman Schwartz's approval rating as Bio-Rad Laboratories' CEO?

325 employees have rated Bio-Rad Laboratories Chief Executive Officer Norman Schwartz on Glassdoor.com. Norman Schwartz has an approval rating of 84% among the company's employees.

What other stocks do shareholders of Bio-Rad Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bio-Rad Laboratories investors own include BioMarin Pharmaceutical (BMRN), Incyte (INCY), Puma Biotechnology (PBYI), AbbVie (ABBV), NVIDIA (NVDA), Broadcom (AVGO), Johnson & Johnson (JNJ), Advanced Micro Devices (AMD), Alibaba Group (BABA) and Intel (INTC).

What is Bio-Rad Laboratories' stock symbol?

Bio-Rad Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "BIO."

Who are Bio-Rad Laboratories' major shareholders?

Bio-Rad Laboratories' stock is owned by a number of retail and institutional investors. Top institutional investors include Veritas Asset Management LLP (2.56%), Brown Advisory Inc. (2.10%), AustralianSuper Pty Ltd (1.29%), Allspring Global Investments Holdings LLC (0.77%), Artemis Investment Management LLP (0.65%) and Assetmark Inc. (0.44%). Insiders that own company stock include Ajit Ramalingam, Annette Tumolo, Giovanni Magni, Ilan Daskal, James R Stark, John Hertia, Michael Crowley, Ronald W Hutton, Timothy S Ernst and Timothy S Ernst.
View institutional ownership trends
.

How do I buy shares of Bio-Rad Laboratories?

Shares of BIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bio-Rad Laboratories' stock price today?

One share of BIO stock can currently be purchased for approximately $520.08.

How much money does Bio-Rad Laboratories make?

Bio-Rad Laboratories (NYSE:BIO) has a market capitalization of $15.45 billion and generates $2.92 billion in revenue each year. The medical research company earns $4.25 billion in net income (profit) each year or ($66.32) on an earnings per share basis.

How many employees does Bio-Rad Laboratories have?

Bio-Rad Laboratories employs 7,900 workers across the globe.

Does Bio-Rad Laboratories have any subsidiaries?

The following companies are subsidiares of Bio-Rad Laboratories: (f/k/a Bio-Rad Laboratories (Israel) Inc.), BIO-RAD spol. s r.o., Bio-Metrics (U.K.) Limited, Bio-Rad, Bio-Rad (Shanghai) Life Science Research & Development Co. Ltd., Bio-Rad 1, Bio-Rad AbD Serotec GmbH, Bio-Rad AbD Serotec Ltd, Bio-Rad China Ltd., Bio-Rad Denmark ApS, Bio-Rad Europe GmbH, Bio-Rad Export LLC, Bio-Rad Finland Oy (f/k/a DiaMed Fennica Oy), Bio-Rad France, Bio-Rad France Holding, Bio-Rad Germany Holding GmbH, Bio-Rad Haifa Ltd., Bio-Rad Holdings LLC, Bio-Rad Hungary Trading LLC, Bio-Rad IHC Europe GmbH, Bio-Rad Innovations, Bio-Rad Korea Ltd., Bio-Rad Laboratories (Canada) Limited, Bio-Rad Laboratories (India) Private Limited, Bio-Rad Laboratories (Pty) Ltd, Bio-Rad Laboratories (Rishon) Inc., Bio-Rad Laboratories (Shanghai) Co. Ltd., Bio-Rad Laboratories (Singapore) Pte Ltd, Bio-Rad Laboratories AB, Bio-Rad Laboratories AG, Bio-Rad Laboratories B.V., Bio-Rad Laboratories Ges.m.b.H., Bio-Rad Laboratories GmbH, Bio-Rad Laboratories K.K., Bio-Rad Laboratories Limited, Bio-Rad Laboratories Logistik GmbH, Bio-Rad Laboratories Ltd., Bio-Rad Laboratories M.EPE, Bio-Rad Laboratories NV, Bio-Rad Laboratories Pty Ltd, Bio-Rad Laboratories S.A., Bio-Rad Laboratories S.r.l., Bio-Rad Laboratories SAS, Bio-Rad Laboratories-Aparelhos e Reagentes para Laboratórios Lda, Bio-Rad Laboratorii OOO, Bio-Rad Laboratórios Brasil Ltda., Bio-Rad Luxembourg S.à r.l., Bio-Rad Medical Diagnostics GmbH, Bio-Rad Middle East FZ-LLC, Bio-Rad Norway AS, Bio-Rad Pacific Limited, Bio-Rad Pasteur, Bio-Rad Polska Sp. z o.o., Bio-Rad QL Inc., Bio-Rad S.A., Bio-Rad Services France, Bio-Rad Services UK Limited, Biotest - Businesses, Blackhawk Biosystems, Bridger Technologies Inc., Celsee, Ciphergen Biosystems - ProteinChip Systems Business, DiaMed (G.B.) Ltd, DiaMed (Schweiz) GmbH, DiaMed Benelux NV, DiaMed Diagnostika Deutschland GmbH, DiaMed France SA, DiaMed GmbH, DiaMed Holding AG, DiaMed Holding GmbH, DiaMed Latino-América S.A., DiaMed S.E.A. Limited, DiaMed Österreich GmbH, Distribudora de Analítica para la Medicina Ibérica S.A.U., Dropworks Inc., GnuBIO Inc., Helix Diagnostics, IMV Medical Information Division Inc., International Marketing Ventures Ltd., MJ GeneWorks, Propel Labs - Cell Sorting System Division, QuantaLife, Quantase Ltd., Raindance Technologies Limited, Raindance Techologies Inc., Research Specialties for Laboratories NV, Respiratory Diagnostics Inc., and Wuxi BioCanal Nano Technology Co. Ltd..
Read More

When was Bio-Rad Laboratories founded?

Bio-Rad Laboratories was founded in 1952.

How can I contact Bio-Rad Laboratories?

Bio-Rad Laboratories' mailing address is 1000 ALFRED NOBEL DRIVE, HERCULES CA, 94547. The official website for the company is www.bio-rad.com. The medical research company can be reached via phone at (510) 724-7000, via email at investor_relations@bio-rad.com, or via fax at 510-741-5817.

This page (NYSE:BIO) was last updated on 8/9/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.